Abstract
The introduction of hyperthermic intraperitoneal chemotherapy (HIPEC) was hoped to transform the management of peritoneal metastases, paving the way for pioneering research. Although, a plethora of published studies on the technique exist, conclusive results stemming from randomized data remain elusive. The aim of this study is to assess the cumulative comprehensive available evidence for the use vs non-use of HIPEC treatment in gastrointestinal and biliary tract (GI) malignancies and set the current standpoint of GI HIPEC research both for prevention (adjuvant) and treatment (metastatic) of peritoneal metastases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
